Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2016) 45 OC8.5 | DOI: 10.1530/endoabs.45.OC8.5

BSPED2016 Oral Communications Oral Communications 8- Diabetes (7 abstracts)

Biomedical outcomes of weight loss associated with intragastric balloon therapy supported by a life style programme in severe adolescent obesity

Pooja Sachdev 1, , Lindsey Reece 2 , Rob Copeland 2 , Mike Thomson 4 , Anuja Natarajan 5 , Jerry Wales 6 & Neil Wright 3

1Academic Unit of Child Health, University of Sheffield, Sheffield, UK; 2Center for Sport and Exercise Science, Sheffield Hallam University, Sheffield, UK; 3Department of Paediatric Endocrinology, Sheffield Children’s Hospital, Sheffield, UK; 4Department of Paediatric Gastroenterology, Sheffield Children’s Hospital, Sheffield, UK; 5Department of Paediatrics, Doncaster and Bassetlaw NHS Foundation Trust, Doncaster, UK; 6Department of paediatric endocrinology, Lady Cilento Children’s Hospital, South Brisbane, Australia.

Background: Severe obesity in childhood is associated with significant morbidity including systolic hypertension, fatty liver, obstructive sleep apnoea, dyslipidemia and type 2 diabetes. Evidence that even small changes in BMI SDS bring about significant clinical benefit is strong.

Objectives: To assess the impact of weight loss associated with intragastric balloon therapy supported by a life style programme on biomedical outcomes (glucose metabolism, blood pressure, lipid profiles) in severely obese adolescents and to observe anychanges in incretin, ghrelin and adipokine hormones.

Methodology: A 2-year cohort study of 12 adolescents (BMI >3.5 SD, Tanner stage >4) following 6 months intragastric balloon placement. Subjects underwent anthropometry, oral glucose tolerance test, measurement of basal and stimulated incretins and adipokines at 0, 6 and 24 months.

Results: Mean weight loss at 6 months was 7.1 kg ([CI −27,12.8], P value=0.005), (5% body weight) but weight loss was sustained in only 20% patients at 2-years. Insulin area under the curve following OGTT improved at 6 months (P<0.05).As individuals tended to regain weight following balloon removal HOMA scores and fasting insulin levels increased but Insulin AUC remained below pre intervention levels. There was also a fall in HBA1c at 6 months that was maintained despite weight regain (P<0.005). There was a significant increase in fasting GLP-1 over the 24 months (P=0.04). The area under the curve (AUC) for GLP-1 also improved at 24 months despite weight regain. The significant drop in GIP at 6 months (P<0.001) was not sustained at 24 months. We noted moderately strong inverse correlations between percentage weight loss and change in GLP-1 AUC (r=−0.45) and ghrelin (r=−0.51) at 6 months. Clinically relevant improvements were also seen in blood pressure, liver function at 6 months.

Conclusion: Short-term weight loss and clinically relevant improvement in obesity related complications were seen after 6 months of intragastric balloon therapy. Benefits were sustained in some patients but not the majority at 2 years.

Volume 45

44th Meeting of the British Society for Paediatric Endocrinology and Diabetes

British Society for Paediatric Endocrinology and Diabetes 

Browse other volumes

Article tools

My recent searches

No recent searches.